Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant
Gautam Mehta,Antonio Riva,Maria Pilar Ballester,Eva Uson,Montserrat Pujadas,Ângela Carvalho-Gomes,Ivan Sahuco,Ariadna Bono,Federico D'Amico,Raffaela Viganò,Elena Diago,Beatriz Tormo Lanseros,Elvira Inglese,Dani Martinez Vazquez,Rajni Sharma,Hio Lam Phoebe Tsou,Nicola Harris,Annelotte Broekhoven,Marjolein Kikkert,Shessy P Torres Morales,Sebenzile K Myeni,Mar Riveiro-Barciela,Adriana Palom,Nicola Zeni,Alessandra Brocca,Annarosa Cussigh,Sara Cmet,Desamparados Escudero-García,Matteo Stocco,Leonardo Antonio Natola,Donatella Ieluzzi,Veronica Paon,Angelo Sangiovanni,Elisa Farina,Clara di Benedetto,Yolanda Sánchez-Torrijos,Ana Lucena-Varela,Eva Román,Elisabet Sánchez,Rubén Sánchez-Aldehuelo,Julia López-Cardona,Itzel Canas-Perez,Christine Eastgate,Dhaarica Jeyanesan,Alejandro Esquivel Morocho,Simone Di Cola,Lucia Lapenna,Giacomo Zaccherini,Deborah Bongiovanni,Paola Zanaga,Katia Sayaf,Sabir Hossain,Javier Crespo,Mercedes Robles-Díaz,Antonio Madejón,Helena Degroote,Javier Fernández,Marko Korenjak,Xavier Verhelst,Javier García-Samaniego,Raúl J Andrade,Paula Iruzubieta,Gavin Wright,Paolo Caraceni,Manuela Merli,Vishal C Patel,Amir Gander,Agustín Albillos,Germán Soriano,Maria Francesca Donato,David Sacerdoti,Pierluigi Toniutto,Maria Buti,Christophe Duvoux,Paolo Antonio Grossi,Thomas Berg,Wojciech G Polak,Massimo Puoti,Anna Bosch-Comas,Luca Belli,Patrizia Burra,Francesco Paolo Russo,Minneke Coenraad,José Luis Calleja,Giovanni Perricone,Marina Berenguer,Joan Claria,Richard Moreau,Vicente Arroyo,Paolo Angeli,Cristina Sánchez,Javier Ampuero,Salvatore Piano,Shilpa Chokshi,Rajiv Jalan,COBALT Consortium
DOI: https://doi.org/10.1097/HC9.0000000000000273
2023-10-18
Abstract:Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine. Secondary aims included the determination of factors predicting breakthrough infection. Methods: COVID-19 vaccination and Biomarkers in cirrhosis And post-Liver Transplantation is a prospective, multicenter, observational case-control study. Participants were recruited at 4-10 weeks following first and second vaccine doses in cirrhosis [n = 325; 94% messenger RNA (mRNA) and 6% viral vaccine], autoimmune liver disease (AILD) (n = 120; 77% mRNA and 23% viral vaccine), post-liver transplant (LT) (n = 146; 96% mRNA and 3% viral vaccine), and healthy controls (n = 51; 72% mRNA, 24% viral and 4% heterologous combination). Serological end points were measured, and data regarding breakthrough SARS-CoV-2 infection were collected. Results: After adjusting by age, sex, and time of sample collection, anti-Spike IgG levels were the lowest in post-LT patients compared to cirrhosis (p < 0.0001), AILD (p < 0.0001), and control (p = 0.002). Factors predicting reduced responses included older age, Child-Turcotte-Pugh B/C, and elevated IL-6 in cirrhosis; non-mRNA vaccine in AILD; and coronary artery disease, use of mycophenolate and dysregulated B-call activating factor, and lymphotoxin-α levels in LT. Incident infection occurred in 6.6%, 10.6%, 7.4%, and 15.6% of cirrhosis, AILD, post-LT, and control, respectively. The only independent factor predicting infection in cirrhosis was low albumin level. Conclusions: LT patients present the lowest response to the SARS-CoV-2 vaccine. In cirrhosis, the reduced response is associated with older age, stage of liver disease and systemic inflammation, and breakthrough infection with low albumin level.